GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.GAITHERSBURG, Md.--(BUSINESS WIRE)--Mar. 20, 2025--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of March 15, 2025, the compensation committee of GeneDx's board of directors granted 46,340 restricted stock units ("RSUs") to ten newly-hired employees as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx's 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
馬里蘭州蓋瑟斯堡--（商業資訊）--2025年3月20日--GeneDx（納斯達克：WGS），一家通過基因組洞察提供改善健康結果的領導者，今天宣佈，自2025年3月15日起，GeneDx董事會的薪酬委員會向十名新聘員工授予了46,340個限制性股票單位（"RSUs"），作爲每位員工與GeneDx簽訂勞動合同的重要誘因。這些RSUs是根據GeneDx的2023年股權誘導計劃授予的，並符合納斯達克上市規則5635(c)(4)。
The RSUs will vest in equal annual installments over a four-year period, subject to the employee's continued service with GeneDx on each applicable vesting date. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
這些RSUs將在四年內按年度均等分期歸屬，前提是員工在每個適用的歸屬日期繼續爲GeneDx工作。每個RSU代表在結算時獲得1股發行人A類普通股的有條件權利。
About GeneDx
關於 GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.
在GeneDx（納斯達克：WGS），我們相信每個人都應擁有個性化、針對性的醫療保健——這一切都始於基因診斷。憑藉全球最大的稀有疾病數據集之一，我們行業領先的外顯子組和基因組測試將複雜的基因組數據轉化爲臨牀答案，從而解鎖個性化的健康計劃，加速藥物開發，提高醫療系統的效率。有關更多信息，請訪問genedx.com，並在LinkedIn、X、Facebook和Instagram上與我們聯繫。
View source version on businesswire.com:
查看businesswire.com上的源版本：
Investor Relations:
Investors@GeneDx.com
投資者關係：
Investors@GeneDx.com
Media:
Press@GeneDx.com
媒體：
Press@GeneDx.com
Source: GeneDx
來源：GeneDx
譯文內容由第三人軟體翻譯。
，而今天在早盤衝高至24000附近入了熊仔后，指數大幅下跌最多接近6百多點，即時把昨日虧損賺回有突多
，而今天再破新高， 最高 24076 ， 其後收市時轉跌約70點， 出了陰燭， 暫時走勢仍未有破壞， 不過由前底至今已經上漲接近至6千點， 本人覺得有貨者可以繼續持貨直到 明顯有走勢轉壞才止賺離場， 沒貨者可以等待回調后再上車， 其實本人也希望能夠快點有回調， 一來可以上車， 二來回一回氣也健康
，暫時看法都是跟之前一樣， 覺得即使有所回調應該都不會跌得太深，但假若期貨失守22350企不穩收，便可能還有下跌空間， 期貨短期要跌破21400的機會應該也不大， 所以本人覺得如果有大幅的回調也是一個機會分注做多。近日都堅持不過夜持倉，暫只做即市， 因為不高追，也不隨便做空。支持阻力以現貨作參考
支持位 23150，23250，2...
評論(0)
請選擇舉報原因